# A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

> **NCT05975645** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 29 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Penpulimab injection
- **DRUG:** TQB2618 injection
- **DRUG:** Anlotinib Hydrochloride Capsules

## Key facts

- **NCT ID:** NCT05975645
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-15
- **Primary completion:** 2025-06-04
- **Final completion:** 2025-06-04
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975645, "A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05975645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*